Company news
Esperion Therapeutics, Inc. (NASDAQ:ESPR) news
Every Esperion Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Ther...
June 17, 2026
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congres...
May 26, 2026
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Soci...
May 13, 2026
Esperion to be Acquired by ARCHIMED
May 1, 2026
Esperion to Report First Quarter 2026 Financial Results on May 7
April 23, 2026
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nas...
April 2, 2026
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis The...
April 2, 2026
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
March 31, 2026
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s ...
March 30, 2026
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
March 17, 2026
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
March 16, 2026
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 10, 2026
/C O R R E C T I O N -- HLS Therapeutics Inc./
March 5, 2026
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascu...
March 4, 2026
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascu...
March 3, 2026
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10
February 24, 2026
Esperion to Participate in The 2026 Citizens Life Sciences Conference
February 18, 2026
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bemp...
February 17, 2026
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 11, 2026
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
January 11, 2026
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults W...
December 19, 2025
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
November 21, 2025
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
November 19, 2025
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascu...
November 18, 2025
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the ...
November 10, 2025
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
November 6, 2025
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
November 4, 2025
Esperion to Participate in Jefferies Global Healthcare Conference - London
November 3, 2025
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November...
October 28, 2025
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
October 27, 2025
Esperion to Report Third Quarter 2025 Financial Results on November 6
October 23, 2025
Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis
October 16, 2025
Esperion Announces Pricing of Public Offering of Common Stock
October 7, 2025
Esperion Announces Proposed Public Offering of Common Stock
October 7, 2025
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic a...
October 3, 2025
Oritain Extends Cutting-Edge Origin Verification to Leather for EUDR Readiness
September 23, 2025
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
September 19, 2025
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
August 29, 2025
Esperion to Participate in Upcoming September Investor Conferences
August 26, 2025
HLS Therapeutics Announces Q2 2025 Financial Results
August 14, 2025
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
August 5, 2025
Esperion to Report Second Quarter 2025 Financial Results on August 5
July 22, 2025
Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19...
July 8, 2025
Esperion Appoints Craig Thompson to Board of Directors
July 1, 2025
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 1...
June 2, 2025
Esperion to Participate in Upcoming June Investor Conferences
May 20, 2025
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
May 12, 2025
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference
May 9, 2025
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada
May 8, 2025